ACE-Hemmer in der Behandlung der klinischen Herzinsuffizienz

  • Hubert Pouleur

Zusammenfassung

In den vergangenen Jahren haben sich die Inhibitoren des Angiotensin Converting Enzyme (ACE-Hemmer) zu Eckpfeilern in der Behandlung der klinischen Stauungsherzinsuffizienz entwickelt. Es gibt überzeugende Hinweise dafür, daß sie die Überlebenschancen verbessern und daß sie in dieser Hinsicht den gewöhnlichen Vasodilatatoren überlegen sind. Die Gabe von ACE-Hemmern verbessert auch die funktionelle Klasse entsprechend der New York Heart Association und die Funktion des linken Ventrikels, aber ihre Langzeitwirkungen auf die Belastungstoleranz und die Lebensqualität scheinen mäßig zu sein. Während einer Langzeitbehandlung von Patienten mit einer ischämischen Funktionsstörung des linken Ventrikels reduzieren ACE-Hemmer auch signifikant die Inzidenz neu auftretender ischämischer Ereignisse (Myokardinfarkt, instabile Angina).

Schlüsselwörter

Enalapril Captopril Funktion des linken Ventrikels Herzinsuffizienz Überlebenschancen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Araki T, Shimizu M, Sugihara N, Takeda R (1992) Effect of angiotensin converting enzyme inhibitor on myocardial collagen metabolism in cardiomyopathic hamsters. J Moll Cell Cardiol 24: S56Google Scholar
  2. 2.
    Bussman WD, Störger H, Hadler N (1987) Long-term treatment of severe chronic heart failure with captopril: a double-blind, randomized, placebo-controlled, long-term study. J Cardiovasc Pharmacol 9: 550 — S60CrossRefGoogle Scholar
  3. 3.
    Captopril Multicenter Research Group (1983) A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755–763CrossRefGoogle Scholar
  4. 4.
    Chalmers JP, West MJ, Cyran J (1987) Placebo-controlled study of lisinopril in congestive heart failure: a multicenter study. J Cardiovasc Pharmacol 9: S89 — S97PubMedCrossRefGoogle Scholar
  5. 5.
    Cleland JG F, Dargie HJ, Ball SG (1985) Effects of enalapril in heart failure: a double-blind study of effects in exercise performance, renal function, hormones, and metabolic state. Br Heart J 54: 305–312PubMedCrossRefGoogle Scholar
  6. 6.
    Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303–310PubMedCrossRefGoogle Scholar
  7. 7.
    Held P, Swedberg K (1992) ACE-inhibitors in the treatment of heart failure. In: Barnett D, Francis G, Pouleur H (eds) Heart failure: newer therapeutics. Marcel Dekker, Inc. (in press)Google Scholar
  8. 8.
    Hirakata H, Fouad-Tarazi FM, Bumpus FM, Khosla M, Healy B, Husain A et al. (1990) Angiotensins and the failing heart. Enhanced positive inotropic responce to angiotensin I in cardiomyopathic hamster heart in the presence of captopril. Circ Res 66: 891–899PubMedCrossRefGoogle Scholar
  9. 9.
    Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D et al. (1992) Effects of the angiotensin converting enzyme inhibitor enalapril, on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 86: 431–438PubMedCrossRefGoogle Scholar
  10. 10.
    McGrath BP, Arnolda L, Matthews PG (1985) Controlled trial of enalapril in congestive cardiac failure. Br Heart J 54: 405–414PubMedCrossRefGoogle Scholar
  11. 11.
    Pacher R, Globits S, Bergler-Klein J, Kratochwill C, Stefenelli T, Baumgartner W et al. (1992) Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. J Am Coll Cardiol 19: 317Google Scholar
  12. 12.
    Pfeffer MA, Braunwald E (1990) Ventricular remodeling after myocardial infarction Experimental observations and clinical implications. Circulation 81: 1161–1172PubMedCrossRefGoogle Scholar
  13. 13.
    Pouleur H, Konstam MA, van Eyll C, Melin J, Gallagher P, Yusuf S, Rousseau MF, for the SOLVD Investigators (1992) Long-term effects of enalapril on left ventricular diastolic properties: evidence for “reversed remodeling”. Circulation 86: 1–120Google Scholar
  14. 14.
    Remes J, Nikander P, Rehnberg S (1986) Enalapril in chronic heart failure, a double-blind placebo-controlled study. Ann Clin Res 18: 124–128PubMedGoogle Scholar
  15. 15.
    Sharpe DN, Murphy J, Coxon R, Hannan SF (1984) Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70: 271–278PubMedCrossRefGoogle Scholar
  16. 16.
    Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen and CONSENUS Trial Study Group (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82: 1730–1736CrossRefGoogle Scholar
  17. 17.
    The captopril-digoxin multicenter research group (1988) Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 259: 539–544CrossRefGoogle Scholar
  18. 18.
    The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435CrossRefGoogle Scholar
  19. 19.
    The SOLVD Investigators (1990) Studies of left ventricular dysfunction (SOLVD) — Rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 66: 315–322CrossRefGoogle Scholar
  20. 20.
    The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325: 293–302CrossRefGoogle Scholar
  21. 21.
    The SOLVD Investigator (1992) Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 327: 685–691CrossRefGoogle Scholar
  22. 22.
    Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1990) Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66: 883–890PubMedCrossRefGoogle Scholar
  23. 23.
    Vagelos R, Yee G, Boyle M, Moore C, Prikaszky L, Willson K et al. (1992) Failure of low but not high dose chronic enalapril therapy to suppress serum angiotensin converting enzyme ( ACE) activity in heart failure. J Am Coll Cardiol 19: 145Google Scholar
  24. 24.
    Weber KT, Brilla CG (1991) Pathological hypertrophy and cardiac interstitium. Circulation 83 (6): 1849–1865PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Hubert Pouleur
    • 1
  1. 1.Department of Physiology and Pharmacology and Division of CardiologyUniversity of Louvain, School of MedicineBrusselsBelgium

Personalised recommendations